Share Price and Basic Stock Data
Last Updated: December 11, 2024, 9:40 pm
PEG Ratio | 0.49 |
---|
Competitors of Chemo Pharma Laboratories Ltd
Stock Name | Market Cap | Current Price | High / Low | Stock P/E | Book Value | Dividend Yield | ROCE | ROE | Face Value |
---|---|---|---|---|---|---|---|---|---|
Gujarat Themis Biosyn Ltd | 3,552 Cr. | 326 | 390/108 | 67.4 | 20.5 | 0.20 % | 45.0 % | 33.8 % | 1.00 |
Gujarat Terce Laboratories Ltd | 65.3 Cr. | 88.0 | 94.9/26.6 | 25.0 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
Gujarat Inject (Kerala) Ltd | 30.6 Cr. | 20.9 | 20.9/8.62 | 39.8 | 6.64 | 0.00 % | 2.65 % | 2.08 % | 10.0 |
Godavari Drugs Ltd | 92.5 Cr. | 123 | 155/87.0 | 13.9 | 55.4 | 0.00 % | 14.4 % | 15.5 % | 10.0 |
Glenmark Life Sciences Ltd | 12,896 Cr. | 1,050 | 1,335/627 | 30.4 | 207 | 2.14 % | 28.1 % | 21.1 % | 2.00 |
Industry Average | 18,880.41 Cr | 1,235.02 | 57.78 | 186.69 | 0.30% | 16.20% | 16.65% | 6.32 |
Quarterly Result
Month | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Expenses | 0.07 | 0.08 | 0.18 | 0.12 | 0.05 | 0.02 | 0.02 | 0.05 | 0.02 | 0.02 | 0.10 | 0.05 | 0.02 |
Operating Profit | -0.07 | -0.08 | -0.18 | -0.12 | -0.05 | -0.02 | -0.02 | -0.05 | -0.02 | -0.02 | -0.10 | -0.05 | -0.02 |
OPM % | |||||||||||||
Other Income | 0.19 | 0.36 | 0.13 | -0.38 | 0.59 | 0.19 | -0.10 | 0.43 | 0.46 | 0.70 | 0.25 | 0.30 | 0.63 |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Profit before tax | 0.11 | 0.27 | -0.05 | -0.50 | 0.54 | 0.17 | -0.12 | 0.38 | 0.44 | 0.68 | 0.15 | 0.25 | 0.61 |
Tax % | 0.00% | 0.00% | -400.00% | 0.00% | 0.00% | 0.00% | 25.00% | 0.00% | 0.00% | 0.00% | 293.33% | 0.00% | 0.00% |
Net Profit | 0.11 | 0.28 | 0.14 | -0.50 | 0.53 | 0.16 | -0.15 | 0.38 | 0.44 | 0.68 | -0.29 | 0.25 | 0.61 |
EPS in Rs | 0.73 | 1.87 | 0.93 | -3.33 | 3.53 | 1.07 | -1.00 | 2.53 | 2.93 | 4.53 | -1.93 | 1.67 | 4.07 |
Last Updated: November 6, 2024, 7:03 pm
Profit & Loss - Annual Report
Last Updated: Unknown
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Expenses | 0.09 | 0.13 | 0.12 | 0.17 | 0.27 | 0.34 | 0.56 | 0.48 | 0.34 | 0.41 | 0.20 | 0.19 | 0.19 |
Operating Profit | -0.09 | -0.13 | -0.12 | -0.17 | -0.27 | -0.34 | -0.56 | -0.48 | -0.34 | -0.41 | -0.20 | -0.19 | -0.19 |
OPM % | |||||||||||||
Other Income | 0.27 | 0.44 | 0.50 | 0.49 | 5.61 | 1.11 | 0.82 | 1.00 | 0.67 | 0.79 | 0.30 | 1.84 | 1.71 |
Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
Depreciation | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.00 |
Profit before tax | 0.17 | 0.31 | 0.38 | 0.32 | 5.34 | 0.77 | 0.26 | 0.50 | 0.31 | 0.36 | 0.08 | 1.64 | 1.52 |
Tax % | 23.53% | 19.35% | 26.32% | 31.25% | 12.17% | 85.71% | 19.23% | 16.00% | 19.35% | -55.56% | 37.50% | 26.83% | |
Net Profit | 0.14 | 0.24 | 0.28 | 0.22 | 4.68 | 0.10 | 0.21 | 0.42 | 0.25 | 0.56 | 0.05 | 1.20 | 1.08 |
EPS in Rs | 0.93 | 1.60 | 1.87 | 1.47 | 31.20 | 0.67 | 1.40 | 2.80 | 1.67 | 3.73 | 0.33 | 8.00 | 7.20 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
Year | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
---|---|---|---|---|---|---|---|---|---|---|---|
YoY Net Profit Growth (%) | 71.43% | 16.67% | -21.43% | 2027.27% | -97.86% | 110.00% | 100.00% | -40.48% | 124.00% | -91.07% | 2300.00% |
Change in YoY Net Profit Growth (%) | 0.00% | -54.76% | -38.10% | 2048.70% | -2125.14% | 207.86% | -10.00% | -140.48% | 164.48% | -215.07% | 2391.07% |
Chemo Pharma Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | % |
Compounded Profit Growth | |
---|---|
10 Years: | 17% |
5 Years: | 41% |
3 Years: | 68% |
TTM: | 51% |
Stock Price CAGR | |
---|---|
10 Years: | 16% |
5 Years: | 86% |
3 Years: | 67% |
1 Year: | 189% |
Return on Equity | |
---|---|
10 Years: | 4% |
5 Years: | 4% |
3 Years: | 5% |
Last Year: | 10% |
Last Updated: Unknown
Balance Sheet
Last Updated: November 14, 2024, 5:34 pm
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
Reserves | 3.11 | 3.35 | 3.62 | 3.84 | 8.52 | 8.62 | 8.83 | 9.24 | 9.49 | 10.05 | 10.10 | 11.30 | 12.16 |
Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Liabilities | 0.27 | 0.35 | 0.46 | 0.20 | 0.58 | 0.13 | 0.09 | 0.22 | 0.06 | 0.11 | 0.02 | 0.21 | 0.04 |
Total Liabilities | 4.88 | 5.20 | 5.58 | 5.54 | 10.72 | 10.25 | 10.42 | 10.96 | 11.05 | 11.66 | 11.62 | 13.01 | 13.70 |
Fixed Assets | 0.02 | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.07 | 0.05 | 0.04 | 0.03 | 0.02 | 0.02 |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 1.68 | 1.68 | 1.68 | 1.68 | 0.02 | 0.02 | 0.04 | 0.02 | 0.04 | 2.94 | 3.03 | 4.40 | 4.39 |
Other Assets | 3.18 | 3.51 | 3.90 | 3.86 | 10.69 | 10.23 | 10.38 | 10.87 | 10.96 | 8.68 | 8.56 | 8.59 | 9.29 |
Total Assets | 4.88 | 5.20 | 5.58 | 5.54 | 10.72 | 10.25 | 10.42 | 10.96 | 11.05 | 11.66 | 11.62 | 13.01 | 13.70 |
Cash Flow
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | -0.09 | -0.13 | -0.12 | -0.17 | -0.39 | -0.34 | -0.56 | -0.48 | -0.34 | -0.41 | -0.20 | -0.19 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | ||||||||||||
Inventory Days | ||||||||||||
Days Payable | ||||||||||||
Cash Conversion Cycle | ||||||||||||
Working Capital Days | ||||||||||||
ROCE % | 3.70% | 6.55% | 7.62% | 6.12% | 3.62% | 7.60% | 2.54% | 4.75% | 2.85% | 1.33% | 0.78% | 13.28% |
This stock is not held by any mutual fund
Key Financial Ratios
Month | Mar 16 |
---|---|
FaceValue | 10.00 |
Basic EPS (Rs.) | -9.66 |
Diluted EPS (Rs.) | -9.66 |
Cash EPS (Rs.) | -9.66 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 24.49 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 24.49 |
PBDIT / Share (Rs.) | -8.98 |
PBIT / Share (Rs.) | -8.98 |
PBT / Share (Rs.) | -8.98 |
Net Profit / Share (Rs.) | -9.66 |
NP After MI And SOA / Share (Rs.) | -9.66 |
Return on Networth / Equity (%) | -39.44 |
Return on Capital Employeed (%) | -35.51 |
Return On Assets (%) | -37.44 |
Current Ratio (X) | 28.82 |
Quick Ratio (X) | 28.82 |
Enterprise Value (Cr.) | 2.24 |
EV / EBITDA (X) | -1.66 |
Price / BV (X) | 0.72 |
EarningsYield | -0.54 |
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemo Pharma Laboratories Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -35.51% (Industry Average ROCE: 16.06%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -39.44% (Industry Average ROE: 16.08%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 28.82
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 16.7 (Industry average Stock P/E: 47.41)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Pharmaceuticals | 5, Kumud Apartment CHS Ltd., Thane District Maharashtra 421301 | chemopharmalab@gmail.com http://www.thechemopharmalaboratoriesltd.com |
Management | |
---|---|
Name | Position Held |
Mr. Bhavin Sheth | Executive Director & CEO |
Mr. Ashok Somani | Executive Director & CFO |
Mrs. Shanta Somani | Non Executive Director |
Mr. Mathura Prasad Sharma | Independent Director |
Mr. Toby Antony | Independent Director |
Mr. Nandkumar Pareek | Independent Director |
FAQ
What is the latest intrinsic value of Chemo Pharma Laboratories Ltd?
The latest intrinsic value of Chemo Pharma Laboratories Ltd as on 12 December 2024 is ₹150.06, which is 7.19% higher than the current market price of ₹140.00. The stock has a market capitalization of 20.9 Cr. and recorded a high/low of ₹154/43.7 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹12.16 Cr and total liabilities of ₹13.70 Cr.
What is the Market Cap of Chemo Pharma Laboratories Ltd?
The Market Cap of Chemo Pharma Laboratories Ltd is 20.9 Cr..
What is the current Stock Price of Chemo Pharma Laboratories Ltd as on 12 December 2024?
The current stock price of Chemo Pharma Laboratories Ltd as on 12 December 2024 is 140.
What is the High / Low of Chemo Pharma Laboratories Ltd stocks in FY 2024-2025?
In FY 2024-2025, the High / Low of Chemo Pharma Laboratories Ltd stocks is 154/43.7.
What is the Stock P/E of Chemo Pharma Laboratories Ltd?
The Stock P/E of Chemo Pharma Laboratories Ltd is 16.7.
What is the Book Value of Chemo Pharma Laboratories Ltd?
The Book Value of Chemo Pharma Laboratories Ltd is 91.1.
What is the Dividend Yield of Chemo Pharma Laboratories Ltd?
The Dividend Yield of Chemo Pharma Laboratories Ltd is 0.00 %.
What is the ROCE of Chemo Pharma Laboratories Ltd?
The ROCE of Chemo Pharma Laboratories Ltd is 13.3 %.
What is the ROE of Chemo Pharma Laboratories Ltd?
The ROE of Chemo Pharma Laboratories Ltd is 9.67 %.
What is the Face Value of Chemo Pharma Laboratories Ltd?
The Face Value of Chemo Pharma Laboratories Ltd is 10.0.